GlaxoSmithKline (GSK) has agreed to purchase the remaining 36.5% share in GlaxoSmithKline Consumer Healthcare from Novartis for $13bn.

GSK has appointed Citigroup, JP Morgan Cazenove and Greenhill & Co as financial advisors for the transaction.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The acquisition will improve GSK’s capital allocation plan and remove uncertainty regarding the business.

Based in the UK, the acquirer company is a pharmaceutical company, while the target company is a Swiss provider of nutritional and over the counter (OTC) medical products.

Indian pharmaceutical company Bal Pharma has purchased 100% interest in Golden Drugs Pvt. Ltd (Golden Drugs).

The target company is a producer of pharma medicines, paracetamol, tablets and capsules. It will operate as a subsidiary of Bal Pharma upon completion of the acquisition.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Private equity firm NovaQuest Capital Management has acquired specialist pharmaceutical company Cutispharma.

“Indian pharmaceutical company Bal Pharma has purchased 100% interest in Golden Drugs Pvt. Ltd (Golden Drugs).”

Cutispharma has received financing from Goldman Sachs Specialist Lending Group as part of the transaction.

Both companies involved in the transaction are based in the US.

The acquisition will support CutisPharma’s growth plans.

CutisPharma has appointed TAP Advisors as financial advisor for the transaction.

Japanese R&D-driven pharmaceutical company Takeda Pharmaceutical plans to acquire Shire, a biotechnology company based in Ireland.

Takeda will approach Shire regarding a possible offer by April.

China-based pharmaceutical company Hunan Fangsheng Pharmaceutical has agreed to invest $3m in LipoMedics.

The target company is involved in the development of personalised paclitaxel therapy.

The investment will increase Hunan Fangsheng Pharmaceutical’s share in Lipomedics to 35.95%.

India-based import and export company Shree Surgovind Tradelink has agreed to purchase pharmaceutical company RR Lifecare.

RR Lifecare will become a subsidiary of Shree Surgovind Tradelink, upon completion of the acquisition.